May 2025 – Brain Tumor Awareness Month: Sending Strength to Everyone Fighting Brain Cancer
May 2025 – Brain Tumor Awareness Month: Sending Strength to Everyone Fighting Brain Cancer
May is Brain Tumor Awareness Month (BTAM): Bringing Hope to Every Patient
Glioblastoma (GBM) is the most common—and most aggressive—type of brain tumor. Treating it is an immense challenge, as surgery is often complex, and both radiation and chemotherapy can lead to severe side effects, including damage to healthy brain function. Many patients experience cognitive changes during treatment, such as memory loss and difficulty concentrating, which can significantly impact their daily lives and mental well-being.
According to the latest data from the National Brain Tumor Society, an estimated 1 million Americans are currently living with a primary brain tumor. In 2023 alone, approximately 94,000 people were newly diagnosed with brain tumors. Of these, only 71% were benign, while around 29% were malignant. Among the malignant cases, more than half were identified as glioblastoma, the most lethal form. That same year, it was estimated that 18,000 Americans died due to brain tumors. For those diagnosed with malignant brain tumors, the 5-year survival rate is only 35.7%, and for GBM patients, it drops even further to just 6.9%, with a median survival time of about 8 months.
In response to this urgent need, Everfront Biotech developed Cerebraca® Wafer, a novel treatment designed specifically to target the most challenging form of recurrent glioblastoma. The goal is to offer renewed hope and extend survival for patients facing this aggressive disease.
But the battle against brain cancer isn’t only fought by the patient. For caregivers, it is also an emotionally and physically exhausting journey. Learning how to manage stress, seek support, and take breaks when needed is crucial to preserving their own health and strength. Remember—only by caring for yourself can you continue caring for the one you love.
During this Brain Tumor Awareness Month, we invite you to join us in shining a light on the real-life challenges faced by brain tumor patients and their caregivers. Every moment of understanding, every act of kindness, becomes a vital source of strength. Together, through compassion and awareness, we can help illuminate the path ahead.
Brain Cancer Information & Resources
At Everfront Biotech, while we tirelessly pursue the development of innovative treatments, we also strive to provide patients and their families with helpful information. Our goal is to support them in maintaining a positive and proactive mindset throughout their long journey of battling cancer, and to encourage them to face treatment with courage and confidence.
Below, you’ll find a collection of valuable resources that may help you or your loved ones navigate this challenging time:
About GBM (Glioblastoma Multiforme)
An overview of GBM, including background, classifications, and treatment options.
Facing the Challenges of Brain Cancer Treatment
An in-depth look at the complexities of brain cancer treatment and how Cerebraca® Wafer is designed to help overcome those challenges.
Facing Brain Tumors: Is Surgery Still the Best Option?
Covers current treatment strategies, the importance of maximal safe resection, and post-operative care approaches.
Approaching Cancer Treatment with a Positive Attitude
Encouragement for patients to embrace a hopeful perspective—transitioning from fear to acceptance—along with suggestions for providing meaningful emotional support.
Targeting Brain Cancer Stem Cells: A Breakthrough Approach
Details on therapeutic strategies against brain tumor stem cells, precision medicine, and the research behind Cerebraca® Wafer.
Balanced Nutrition for Cancer Patients
Nutritional advice including foods to avoid, balanced meal planning, tips to reduce side effects, and guidance on using nutritional supplements.
Cognitive Changes in Brain Tumor Patients
Explores cognitive challenges associated with brain tumors, how treatment affects brain function, and strategies for cognitive rehabilitation and support.
Empowering Cancer Patients: Enhancing Quality of Life
How drug development efforts are addressing quality-of-life issues and practical guidelines for improving everyday well-being for patients.
Supporting a Loved One Through Every Stage of Brain Cancer
Guidance for caregivers on how to provide emotional and physical support through every phase—from surgery and stabilization to disease progression and end-of-life care.
Investigational Drug
CEREBRACA® WAFER <Phase IIa> >>more
- Cerebraca® Wafer developed by Everfront Biotech Inc. is a therapeutic drug wafer that can be used to treat highly malignant glioblastoma (malignant brain cancer). It can be directly implanted into the brain and slowly releases drugs at a high concentration, high penetration, and long duration for about 1 month, exerting a multi-target effect (EF-API-001) that helps to treat cancer and make cancer cells more susceptible to chemotherapy or immune cell killing.
- Glioblastoma multiforme (GBM) is a highly malignant primary brain tumor that can grow up to 16 times its original size within a month. It has a high rate of recurrence after surgical resection, and there are currently no effective treatment options available.
- EF-API-001, the small molecule active pharmarceutical ingredient in Cerebraca® Wafer, has the following characteristics:
- Targeting Axl-1 receptor tyrosine kinase: effectively inhibits the growth and metastasis of brain tumor stem cells.
- Inhibiting the PD-L1 immune checkpoint: reduces the immune suppressive nature of the tumor microenvironment, thus preserving the activity of immune cells to kill tumor cells.
- Inhibition of MGMT DNA repair enzyme: overcomes resistance to Temozolomide (chemotherapy drug) and enables cancer cells to be killed again by chemotherapy.
- Cerebraca® Wafer, its small molecule active ingredient and biodegradable polymer are all manufactured by internationally renowned PIC/S GMP pharmaceutical companies in Taiwan to ensure high quality and reliable aseptic manufacturing processes.
